BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CMX157: Phase I data

A double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 48 healthy volunteers showed that single doses of 25-400 mg oral CMX157 were well tolerated. Additionally,...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >